Please login to the form below

Not currently logged in
Email:
Password:

Esbriet

This page shows the latest Esbriet news and features for those working in and with pharma, biotech and healthcare.

Ocrevus helps Roche shrug off biosimilars in 2018

Ocrevus helps Roche shrug off biosimilars in 2018

New haemophilia drug Hemlibra (emicizumab) added 224m francs, which Schwan said was ahead of expectations – and Esbriet (pirfenidone) for lung disease idiopathic pulmonary fibrosis (IPF) brought in just over 1bn francs,

Latest news

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    The prize: the FDA designated “breakthrough therapy” pirfenidone (Esbriet), an orally active small molecule, anti-fibrotic agent that inhibits the synthesis of both TGF-beta and TNF-alpha. Pirfenidone is under

  • Orphan indication? No easy access Orphan indication? No easy access

    Only the case of Intermune's idiopathic pulmonary fibrosis drug Esbriet (perfenidone) was the balance of benefit and risk to patients considered and a finding of 'no proven added benefit' was

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Out of the 10 products assessed last year, four have obtained poor innovation scores: Esbriet (pirfenidone), Livazo (pitavastatin), Yellox (bromfenac) and Trajenta (linagliptin) and a majority of manufacturers have struggled – sometimes

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics